Transdifferentiation of high-grade B-cell lymphoma with MYC and BCL2 rearrangements into histiocytic sarcoma after CAR T-cell therapy: a case report-Reference-Cited by-同舟云学术

Transdifferentiation of high-grade B-cell lymphoma with MYC and BCL2 rearrangements into histiocytic sarcoma after CAR T-cell therapy: a case report

Published:2022-10-21 Issue:4 Volume:15 Page:229-237
ISSN:1868-9256
Container-title:Journal of Hematopathology
language:en
Short-container-title:J Hematopathol

Author:

Gauto-Mariotti Estefania^ORCID,Nguyen Amanda J.,Waters Chloe,Scurti Gina M.,Haddad Sandra,Velankar Milind M.,Dalheim Annika V.,Dronzek Victoria,Ketterling Rhett P.,Nishimura Michael I.,Dalland Joanna C.,Hossain Nasheed M.

Publisher

Springer Science and Business Media LLC

Subject

Hematology,Histology,Pathology and Forensic Medicine

Link

https://link.springer.com/content/pdf/10.1007/s12308-022-00519-2.pdf

Reference29 articles.

1. Neelapu SS, Locke FL, Bartlett NL, Lekakis LJ, Miklos DB, Jacobson CA, Braunschweig I, Oluwole OO, Siddiqi T, Lin Y, Timmerman JM, Stiff PJ, Friedberg JW, Flinn IW, Goy A, Hill BT, Smith MR, Deol A, Farooq U, McSweeney P, Munoz J, Avivi I, Castro JE, Westin JR, Chavez JC, Ghobadi A, Komanduri Kv, Levy R, Jacobsen ED, Witzig TE, Reagan P, Bot A, Rossi J, Navale L, Jiang Y, Aycock J, Elias M, Chang D, Wiezorek J, Go WY (2017) Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma. New England J Med 377:2531–2544. https://doi.org/10.1056/nejmoa1707447

2. Wei J, Mao Z, Wang N, Huang L, Cao Y, Sun W, Long X, Tan J, Li C, Xiao Y, Gu C, Zhang S, Zhang Y, Zhang T, Zhou J, Huang L (2020) Long‐term outcomes of relapsed/refractory double‐hit lymphoma (r/r DHL) treated with CD19/22 CAR T‐cell cocktail therapy. Clin Transl Med 10. https://doi.org/10.1002/CTM2.176

3. Mohty M, Dulery R, Jordan G, Malard F, Brissot E, Aljurf M, Bazarbachi A, Christian C, Kharfan-Dabaja MA, BipinSavani N, Huang H, SaadKenderian S, Miguel-Angel P, Yakoub-Agha I, Nagler A (2020) CAR T-cell therapy for the management of refractory/relapsed high-grade B-cell lymphoma: a practical overview. Bone Marrow Transplant 55:1525–1532. https://doi.org/10.1038/s41409-020-0892-7

4. Singh N, Orlando E, Xu J, Xu J, Binder Z, Collins MA, O’Rourke DM, Melenhorst JJ (2020) Mechanisms of resistance to CAR T cell therapies. Semin Cancer Biol 65:91–98. https://doi.org/10.1016/j.semcancer.2019.12.002

5. Laurent C, Syrykh C, Hamon M, Adélaïde J, Guille A, Escudié F, Jalowicki G, Fina F, Bardet A, Mescam L, Molina TJ, Dartigues P, Parrens M, Sujobert P, Besson C, Birnbaum D, Xerri L (2021) Resistance of B-cell lymphomas to CAR T-cell therapy is associated with genomic tumor changes which can result in transdifferentiation. Am J Surg Pathol Publ Ah:1–12. https://doi.org/10.1097/pas.0000000000001834

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Complete loss of lineage defining antigens in two cases of B-cell malignancies following CAR-T therapy;Journal of Hematopathology;2024-08-26

2. Histiocytic sarcoma following CAR T-cell therapy: a case report;International Journal of Hematology;2024-01-31